The global oligonucleotide synthesis market continues to gain remarkable momentum, emerging as one of the fastest-growing segments within the broader life sciences and biotech industry. Valued at US$8.9 billion in 2024, rising to US$10.5 billion in 2025, the market is projected to surge to a striking US$24.7 billion by 2030, driven by a powerful 18.6% CAGR.
This exponential growth signals a new era of RNA-based therapeutics, precision medicine, and high-throughput genetic engineering.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Why Oligonucleotides Are Becoming the Backbone of Modern Medicine
The rising demand for custom DNA/RNA oligos, advanced ASO therapies, and siRNA-based drugs has transformed the industry landscape. A few major forces shaping the market include:
1️⃣ Rapid Adoption in Therapeutics & Diagnostics
Oligonucleotides are now foundational to:
-
Gene modulation therapies
-
Rare disease treatments
-
Oncology-targeted therapeutics
-
Infectious disease diagnostics
-
CRISPR gene-editing systems
As precision medicine becomes mainstream, custom oligo synthesis is no longer optional—it’s mission-critical.
2️⃣ Surge in Synthetic Biology & Life Sciences Research
From design-to-delivery platforms to modular DNA engineering, oligos underpin:
-
mRNA vaccine development
-
Gene circuit design
-
Protein expression optimization
-
High-throughput screening
Investment in synthetic biology infrastructure—especially in emerging economies—is unlocking massive new revenue opportunities.
3️⃣ R&D Boom + Favorable Regulatory Support
Landmark approvals of antisense therapies like:
-
Nusinersen (spinal muscular atrophy)
-
Inotersen (hereditary ATTR amyloidosis)
…have propelled confidence among investors, regulators, and clinicians, accelerating commercialization timelines.
Product Insights: ASOs Lead the Charge in 2024
Among product segments, antisense oligonucleotide (ASO)-based drugs dominated the market in 2024.
Why ASOs Are Taking Over:
-
High versatility in gene expression modulation
-
Lower manufacturing complexity compared to other RNA modalities
-
Growing demand for rare disease therapeutics
-
Mature delivery platforms
-
Expanding commercial success supported by robust clinical pipelines
ASOs have established themselves as the cornerstone of next-gen RNA therapeutics—a trend expected to strengthen through 2030.
Market by End User: Hospitals Lead Due to Rising Precision Medicine Adoption
In 2024, hospitals held the largest market share, driven by:
-
Increased use of oligo-based therapies in neurology and rare genetic disorders
-
Growing patient pool requiring targeted, RNA-based treatments
-
Expansion of precision medicine programs
-
Increasing availability of oligo-based companion diagnostics
As chronic and infectious diseases escalate, hospitals are becoming central hubs for advanced RNA therapeutics delivery.
Regional Spotlight: North America Stays on Top
North America led the market in 2024 thanks to:
-
Strong presence of leading manufacturers
-
FDA- and Health Canada-friendly regulatory environment
-
Rapid commercialization cycles
-
Strong academic-industrial collaboration networks
-
High investments in genomic medicine and synthetic biology
This region will likely continue to dominate due to next-gen manufacturing capabilities and ongoing expansions in therapeutic oligonucleotide production.
Who’s Leading the Market? Key Players to Watch
Major companies shaping the oligonucleotide synthesis landscape include:
-
Danaher Corporation
-
Thermo Fisher Scientific
-
Merck KGaA
-
Eurofins Scientific
-
Agilent Technologies
-
Twist Bioscience
-
GenScript
-
Maravai LifeSciences
-
LGC Limited
-
Kaneka Corporation
-
Azenta Life Sciences
Player Spotlight: IDT (Danaher)
-
Expansion of cutting-edge cGMP oligo manufacturing
-
New Iowa facility equipped with ISO cleanrooms and QC labs
-
Strengthening foothold in therapeutic-grade oligo production
Thermo Fisher Scientific
-
Deep portfolio in custom primers, probes, DNA/RNA oligos
-
Strong global presence and expansion across 50+ countries
-
Advances in mRNA & oligo analytics through academic partnerships
Biogen
-
Manufacturing leadership in antisense oligo-based drugs like Spinzara
-
FDA accelerated approval of QALSODY (Tofersen)
-
New collaboration with Stoke Therapeutics (2025) for Zorevunersen
Trending Now: What’s Shaping the Future of the Oligonucleotide Synthesis Market?
Here are the hottest trends driving 2025–2030 growth:
1. Rise of AI-Driven Oligo Design Platforms
Machine learning tools are assisting in:
-
Predictive oligo binding
-
Off-target minimization
-
Automated synthesis route optimization
-
Faster research cycles
2. CRISPR 3.0 and Next-Generation Gene Editing
Demand for:
-
sgRNAs
-
HDR templates
-
Repair oligos
…continues to spike as CRISPR expands into clinical gene correction.
3. GMP-Scale RNA Manufacturing Booms
Therapeutic demand is pushing scaling capabilities:
-
mRNA vaccine pipelines
-
siRNA therapies
-
ASO production
-
Novel RNA delivery systems
4. Miniaturized, Automated Synthesizers
Portable, benchtop, AI-enabled synthesizers are reshaping:
-
Academic research
-
Personalized medicine
-
Point-of-care oligo production
5. Oligos in Liquid Biopsy and Companion Diagnostics
Precision oncology is fueling:
-
Tumor mutation tracking
-
ctDNA assays
-
Early disease detection platforms
6. Increasing Collaborations Across Biotech & CRO/CMO Ecosystems
Tech-transfer and manufacturing outsourcing are becoming essential to scale RNA therapeutics globally.
Final Takeaway
The oligonucleotide synthesis market is on a trajectory to redefine the future of therapeutics, diagnostics, and synthetic biology. With strong demand across precision medicine, RNA therapies, genetic disease treatment, and biotechnology R&D, the sector is poised for explosive growth through 2030.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350